Cronos Group (TSE:CRON) Trading Down 4.1% – What’s Next?

Cronos Group Inc. (TSE:CRON)’s share price traded down 4.1% on Tuesday . The company traded as low as C$3.76 and last traded at C$3.77. 203,340 shares were traded during mid-day trading, an increase of 15% from the average session volume of 177,206 shares. The stock had previously closed at C$3.93.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. TD boosted their target price on shares of Cronos Group from C$4.50 to C$5.50 and gave the stock a “buy” rating in a report on Tuesday, May 12th. TD Securities set a C$4.50 target price on shares of Cronos Group and gave the stock a “buy” rating in a report on Tuesday, February 24th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of C$4.75.

Cronos Group Stock Performance

The business’s fifty day moving average price is C$3.63 and its two-hundred day moving average price is C$3.63. The company has a debt-to-equity ratio of 0.12, a quick ratio of 24.01 and a current ratio of 21.87. The stock has a market capitalization of C$1.41 billion, a P/E ratio of -188.00, a P/E/G ratio of 0.12 and a beta of 1.12.

Cronos Group (TSE:CRON) last issued its quarterly earnings results on Monday, May 11th. The company reported C$0.06 EPS for the quarter. The company had revenue of C$62.86 million for the quarter. Cronos Group had a negative net margin of 1.29% and a negative return on equity of 0.19%. As a group, sell-side analysts forecast that Cronos Group Inc. will post -0.26 earnings per share for the current year.

About Cronos Group

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S.